Microglia activity can drive excessive synaptic loss during the prodromal phase of Alzheimer's disease (AD) and is associated with lowered cyclic adenosine monophosphate (cAMP) due to cAMP phosphodiesterase 4B (PDE4B). This study aimed to investigate whether long-term inhibition of PDE4B by A33 (3 mg/kg/day) can prevent synapse loss and its associated cognitive decline in APPswe/PS1dE9 mice. This model is characterized by a chimeric mouse/human APP with the Swedish mutation and human PSEN1 lacking exon 9 (dE9), both under the control of the mouse prion protein promoter. The effects on cognitive function of prolonged A33 treatment from 20 days to 4 months of age, was assessed at 7-8 months. PDE4B inhibition significantly improved both the working and spatial memory of APPswe/PSdE9 mice after treatment ended. At the cellular level, in vitro inhibition of PDE4B induced microglial filopodia formation, suggesting that regulation of PDE4B activity can counteract microglia activation. Further research is needed to investigate if this could prevent microglia from adopting their 'disease-associated microglia (DAM)' phenotype in vivo. These findings support the possibility that PDE4B is a potential target in combating AD pathology and that early intervention using A33 may be a promising treatment strategy for AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201979 | PMC |
| http://dx.doi.org/10.3390/cells13121000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases.
RMD Open
December 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs) or rheumatic musculoskeletal disorder-associated ILDs. SARD-ILDs result in substantial morbidity and mortality, and there is a high medical need for effective therapies that target both fibrotic and inflammatory pathways in SARD-ILD. Phosphodiesterase 4 (PDE4) hydrolyses cyclic AMP, which regulates multiple pathways involved in inflammatory processes.
View Article and Find Full Text PDFMenisoxoisoaporphine A, a novel oxoisoaporphine alkaloid from Menispermi Rhizoma, inhibits inflammation by targeting PDE4B.
Front Pharmacol
December 2024
School of Pharmacy, Shanxi Medical University, Taiyuan, China.
Background: Dysregulated and excessive inflammatory reactions can lead to tissue damage, which is the underlying cause of most human diseases. Menisoxoisoaporphine A (MA), a novel oxoisoaporphine alkaloid, was obtained from Menispermi Rhizoma, a traditional Chinese medicinal herb used in the treatment of inflammatory conditions in clinical practice. This suggests that MA has very promising potential for the development of anti-inflammatory therapeutics.
View Article and Find Full Text PDFChemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors.
J Invest Dermatol
November 2024
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address:
Article Synopsis
- - Roflumilast is the third PDE4 inhibitor used in dermatology for topical treatments of conditions like psoriasis and dermatitis, while earlier drugs like apremilast and crisaborole target oral and topical usage differently.
- - It is the most effective among the three inhibitors, showcasing a significantly lower IC value of 0.7 nM, compared to apremilast (0.14 μM) and crisaborole (0.24 μM), suggesting much greater potency.
- - The study highlights how PDE4 inhibitors improve anti-inflammatory responses by prolonging cAMP signals within immune cells, and discusses potential chemical modifications to enhance their effectiveness based on newly identified invariant residues and metal ion interactions in their catalytic domains
PDE4B abrogation extenuates angiotensin II-induced endothelial dysfunction related to hypertension through up-regulation of AMPK/Sirt1/Nrf2/ARE signaling.
Tissue Cell
December 2024
Cardiovascular Department, Yueqing Second People's Hospital, Hongqiao Town, Yueqing City, Zhejiang Province 325608, China.
Endothelial dysfunction is commonly perceived as a precursor in the process of hypertension, a severe cardiovascular disorder. Phosphodiesterase 4B (PDE4B) inactivation has been proposed to exert cardioprotective effects and prevent pulmonary hypertension. However, the role of PDE4B in endothelial dysfunction in hypertension remains inexplicit, which will be investigated in the present work.
View Article and Find Full Text PDFRationale design and synthesis of new roflumilast analogues as preferential selective and potent PDE-4B inhibitors.
Bioorg Chem
December 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt; Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad 10023, Iraq. Electronic address:
Article Synopsis
- - In this study, researchers created new compounds based on roflumilast to specifically inhibit the PDE-4B enzyme, using a set of synthesized compounds (4a-u, 5a-i, and 6) that were tested against PDE-4B and compared to roflumilast.
- - Four compounds (4i, 4k, 4p, and 4q) showed strong inhibitory activity with 4p being the most potent (IC = 5.50 nM), even outperforming roflumilast (IC = 2.36 nM) in terms of potency.
- - The selective inhibition characteristics of these compounds were analyzed, with compound 4k
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!